Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07561450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Demodex Blepharitis in Scleral Lens Wearers

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Aug 2026 → Dec 31, 2026
See other at-risk trials from Boston Sight

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Primary completion pushed from Aug 2026 to Dec 31, 2026
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 11 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Boston Sight
2 trials monitored
See 1 trial at risk
The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance. The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.
Trial Details
NCT Number NCT07561450
Lead Sponsor Boston Sight
Conditions
(from sponsor)		 Demodex Blepharitis
Related terms Blepharitis
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov